Long-Term Outcomes of 9-Week vs 1-Year Trastuzumab for Early HER2-Positive Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial
J. Clin. Oncol 2023 Sep 25;[EPub Ahead of Print], P Conte, G Bisagni, F Piacentini, S Sarti, S Minichillo, E Anselmi, M Aieta, V Gebbia, A Schirone, A Musolino, O Garrone, A Beano, A Rimanti, F Giotta, A Turletti, F Miglietta, MV Dieci, R Vicini, S Balduzzi, R D'Amico, V GuarneriFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.